Johnson & Johnson SEC filings, summarized
We read every Johnson & Johnson 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track JNJ in your inbox
Add Johnson & Johnson to your watchlist — free, every morning.
Recent filings
Johnson & Johnson reports 5.9% sales growth and raises 2026 guidance
Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion for the period ended September 27, up 5.9% from a year earlier, while adjusted EPS was…
JNJ EVP Timothy Schmid sells $9.2M in stock
Timothy Schmid, Johnson & Johnson’s EVP and worldwide chair of MedTech, sold 33,597 shares in two open-market transactions on September 2 at $274.74 per…
J&J EVP Jennifer Taubert sells $4.0M in stock
Jennifer L. Taubert, Johnson & Johnson’s EVP, Worldwide Commercialization, Innovative Medicine, sold 15,000 common shares on Aug. 17 at $263.36 per share,…
J&J CEO Joaquin Duato sells approximately $32.2M in stock
Joaquin Duato, Johnson & Johnson’s CEO, chairman of the board and director, sold 20,976 shares at $262.00 each for approximately $5.5 million and 102,315…
J&J CEO Joaquin Duato sells approximately $12.5M in stock
Joaquin Duato, Johnson & Johnson’s CEO, chairman and director, sold 41,957 shares at $258.06 each for approximately $10.83 million and 6,523 shares at…
J&J Chief Legal Officer sells $4.1M in stock
Elizabeth Forminard, Johnson & Johnson’s executive vice president and chief legal officer, sold 9,344 shares at $257.75 each for approximately $2.41 million…
J&J names Tom Cavanaugh to lead Innovative Medicine as Jennifer Taubert retires
Jennifer Taubert will retire as Johnson & Johnson’s Executive Vice President and Worldwide Chairman of Innovative Medicine on September 1, 2026, after more…
J&J completes Firefly acquisition and announces $2.58 billion Sail option
On July 29, 2026, Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, which will result in an approximately $1 billion in-process…
Johnson & Johnson Reaches Proposed $5.5 Billion Ovarian Talc Settlement
Johnson & Johnson agreed to a proposed resolution of about 76,000 remaining ovarian talc claims, subject to participation by plaintiff firms representing at…
J&J EVP Vanessa Broadhurst sells $5.8M in stock
Vanessa Broadhurst, Johnson & Johnson’s EVP of Global Corporate Affairs, sold 23,054 shares on the open market at $251.27 per share, for approximately…
Johnson & Johnson filed an 8‑K (Item 9.01) with a press release dated Jan 21, 2026 for the period ended…
Johnson & Johnson filed an 8‑K (Item 9.01) with a press release dated Jan 21, 2026 for the period ended Dec 28, 2025. Earnings release available as Exhibit…
📢 Johnson & Johnson filed an 8‑K on Jan 21, 2026 announcing sales and earnings for Q4 and FY ended Dec…
📢 Johnson & Johnson filed an 8‑K on Jan 21, 2026 announcing sales and earnings for Q4 and FY ended Dec 28, 2025. Press release attached as Exhibit 99.1.…